References
- Geller J Albert J Geller S Lopez D Cantor T Yen S Effect of megestrol acetate (Megace®) on steroid metabolism and steroid-protein binding in the human prostate J Clin Endocrinol Metab 1976 43 5 1000 1008 62759
- Zhan P Wang Q Qian Q Yu LK Megestrol acetate in cancer patients with anorexia-cachexia syndrome: a meta-analysis Transl Cancer Res 2013 2 2 74 79
- Femia RA Goyette RE The science of megestrol acetate delivery: potential to improve outcomes in cachexia BioDrugs 2005 19 3 179 187 15984902
- Yeh SS Lovitt S Schuster MW Pharmacological treatment of geriatric cachexia: evidence and safety in perspective J Am Med Dir Assoc 2007 8 6 363 377 17619035
- Deschamps B Musaji N Gillespie JA Food effect on the bioavailability of two distinct formulations of megestrol acetate oral suspension Int J Nanomedicine 2009 4 185 192 19774117
- Yeh SS Schuster MW Megestrol acetate in cachexia and anorexia Int J Nanomedicine 2006 1 4 411 416 17722275
- Sylvestre JP Tang MC Furtos A Nanonization of megestrol acetate by laser fragmentation in aqueous milieu J Control Release 2011 149 3 273 280 21047539
- Food and Drug Administration, Center for Drug Evaluation and Research Megace® ES (625 mg/5 mL). Clinical pharmacology and biopharmaceutics review Available from: http://www.accessdata.fda.gov/drugsatfda_docs/nda/2005/021778s000_ClinPharmR.pdf Accessed December 12, 2013
- Farinha A Bica A Tavares P Improved bioavailability of a micronized megestrol acetate tablet formulation in humans Drug Dev Ind Pharm 2000 26 5 567 570 10789071
- Gaver RC Movahhed HS Farmen RH Pittman KA Liquid chromatographic procedure for the quantitative analysis of megestrol acetate in human plasma J Pharm Sci 1985 74 6 664 667 4020655
- Bosch HW Pharmaceutical applications of finely dispersed systems Stauffer DR High Speed Serdes Devices and Applications New York, NY Springer 2008
- Huang Y Luo X You X Xia Y Song X Yu L The preparation and evaluation of water-soluble SKLB610 nanosuspensions with improved bioavailability J Pharm Sci 2013 14 3 1236 1243
- Wu Y Loper A Landis E The role of biopharmaceutics in the development of a clinical nanoparticle formulation of MK-0869: a Beagle dog model predicts improved bioavailability and diminished food effect on absorption in human Int J Pharm 2004 285 1 135 146 15488686
- Mauludin R Nanosuspensions of poorly soluble drugs for oral administration Berlin, Germany Freie Universitat Berlin 2009 Available from: http://elib-a.ucl.ac.uk/full.php?id=596627. Published 2009 Accessed December 12, 2013
- Graham KK Mikolich DJ Fisher AE Posner MR Dudley MN Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients J Acquir Immune Defic Syndr 1994 7 6 580 586 8176641
- Megace® oral suspension [package insert] Princeton, NJ, USA Bristol-Myers Squibb Company 2012